Savaria Corp

SIS-T

It’s in a nice uptrend and is coming back to consolidation levels. He would say the exit point is around $13.25. Technically, everything looks good.

(A Top Pick Nov 18/18, Down 9%) Overall it has been down because they did acquisitions and margins are staring to slip. The last quarter looks good. He thinks it will get back to buying companies. It is going to have a rising tide in terms of demand.

(A Top Pick Mar 29/19, Down 8%) A small cap that specializes in wheelchair elevators in homes and vehicles. None of us are getting younger, and demand will go up. A buying opportunity. It's a long term play at a 3 to 5 year view.

He sold a lot of this in the high-teens when the valuation got ahead of itself. He wants to buy back, but first needs to see organic growth in stair lifts, for example. SIS also needs to better integrate acquisitions. But he likes the managers and this sector. Insiders just bought more share and increased the dividend.

Doesn't like the chart now, after falling from $18. It's breaking below support.

A health care product provider. They had been on an acquisition spree but margins were slipping and they have been trying to improve them. He thinks they will get growth back to the name but he would wait for their earnings report.

Feb.15-June 2 is seasonality, but we see lower lows and lower highs. If this doesn't hold at $12, this will fall lower. Wait till momentum improves.

Likes its growth by acquisition. Great operator. They've said they need to consolidate. Top line growth will be slower. Margin issues. It's a pause. If you like trading, get out and get back in later. Five years out, she'd own it. But looking 5 months out, no need to own.

It is a core investment for him. They made a lot of acquisitions and ran into challenges, as is common. They have to beef up the executive team over time. The balance sheet is in very solid shape.

Maker of in-home elevators and lifts. Acquisitions make up a large part of what they do. Recent earnings were pretty good and analysts generally favour it. Sales were up 50%, but earnings were down. For that reason he is not holding it. He thinks they will eventually get back on track.

Revenue growth has been astounding. Fundamentals are supporting it. But not doing anything technically, so no enticement to get in. Moving averages are trending lower. Not much momentum behind positive moves. Technicals do not support an entry.

52% payout ratio, so the dividend is sustainable. Earnings estimates have been shaved 25%. Not a cheap stock. Free cash flow is slightly positive. He wouldn't enter it now, because their recent reports have disappointed, but you should be okay for at least three years if you already own it. It's a growth-by-acquisition story.

It pulled back in late-2018 then has been sideways. As long as it doesn't break below $12, he's okay with it.

Trimmed at $20. Likes the company and the business. Management is terrific. Hold on to shares at $13. Wait for earnings to buy more. Consolidating the industry. Stock's come down on revised guidance. It's a wait and see before reloading to a full position.

A small cap and a huge success, but it has sold off 23% in the past year. Revenues came in okay, but the EBITDA was only $40 million, instead of $44 million. They made two big acquisitons last year: a medical bedmaker and a Swiss rival. It's a reasonable 18.5x earnings and pays a 3% dividend. It's a play on aging demographics. (Analysts’ price target is $17.63)